TransCode Therapeutics Inc RNAZ
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
TransCode Therapeutics to Host R&D Webcast on June 18, 2026
-
TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer
-
TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer
-
TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University
Trading Information
- Previous Close Price
- $8.83
- Day Range
- $7.94–9.12
- 52-Week Range
- $0.00–20.99
- Bid/Ask
- $6.98 / $10.32
- Shares Outstanding
- 950,302.00
- Market Cap
- $8.13M
- Volume/Avg
- 25,209 / 58,142
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 12
Valuation
|
Metric
|
RNAZ
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.38 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
RNAZ
Financial Strength
|
Metric
|
RNAZ
|
|---|---|
Quick Ratio | 2.39 |
Current Ratio | 3.11 |
Interest Coverage | −6,162.38 |
Quick Ratio
RNAZ
Profitability
|
Metric
|
RNAZ
|
|---|---|
Return on Assets (Normalized) | −47.33% |
Return on Equity (Normalized) | −556.45% |
Return on Invested Capital (Normalized) | −52.32% |
Return on Assets
RNAZ
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<!plZP | LOCK|?&!Ct | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|G$?QGJ$ | LOCK|%S$% | $70B | |||
| argenx SE ADR
ARGX
| LOCK|h?#?>Kn | LOCK|$$ | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Jxc$%%Y | LOCK|l#@zN | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%tl>&T^ | LOCK|?m | $36B | |||
| Moderna Inc
MRNA
| LOCK|w%%VVQK | LOCK|$J> | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|#&l>V%Xv | LOCK|^!Gs | $25B | |||
| Incyte Corp
INCY
| LOCK|K<zYY< | LOCK|$dx | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|MH%$Q& | LOCK|JT! | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|%^&qjh | LOCK|wK | $17B |
United States